Total Payments
$593,484
2024 Payments
$11,949
Companies
14
Transactions
207
Medicare Patients
639
Medicare Billing
$56,500
Payment Breakdown by Category
Research$536,391 (90.4%)
Consulting$48,955 (8.2%)
Other$5,100 (0.9%)
Travel$2,120 (0.4%)
Food & Beverage$917.79 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $536,391 | 166 | 90.4% |
| Consulting Fee | $48,955 | 14 | 8.2% |
| Honoraria | $3,600 | 1 | 0.6% |
| Travel and Lodging | $2,120 | 9 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,500 | 1 | 0.3% |
| Food and Beverage | $917.79 | 16 | 0.2% |
Payments by Type
Research
$536,391
166 transactions
General
$57,093
41 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ironwood Pharmaceuticals, Inc | $501,867 | 151 | $0 (2019) |
| Bausch Health US, LLC | $33,657 | 16 | $0 (2019) |
| Intercept Pharmaceuticals, Inc. | $12,029 | 10 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $10,908 | 4 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $10,083 | 7 | $0 (2020) |
| Mallinckrodt Hospital Products Inc. | $8,147 | 2 | $0 (2021) |
| Gilead Sciences, Inc. | $6,675 | 9 | $0 (2019) |
| Novo Nordisk Inc | $6,000 | 1 | $0 (2021) |
| AstraZeneca UK Limited | $1,611 | 1 | $0 (2023) |
| Otsuka Pharmaceutical Co., Ltd. | $1,500 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,949 | 3 | Intercept Pharmaceuticals, Inc. ($7,417) |
| 2023 | $7,986 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($6,375) |
| 2021 | $11,075 | 3 | Novo Nordisk Inc ($6,000) |
| 2020 | $13,234 | 11 | Intercept Pharmaceuticals, Inc. ($4,612) |
| 2019 | $539,437 | 171 | Ironwood Pharmaceuticals, Inc ($499,860) |
| 2018 | $7,605 | 13 | Gilead Sciences, Inc. ($6,597) |
| 2017 | $2,198 | 3 | Ironwood Pharmaceuticals, Inc ($1,408) |
All Payment Transactions
207 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/11/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Consulting Fee | Cash or cash equivalent | $7,416.52 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 02/02/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) | ||||||
| 01/08/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,532.70 | General |
| 11/03/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $875.00 | Research |
| Study: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) | ||||||
| 10/04/2023 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $5,500.00 | General |
| 08/04/2023 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,611.00 | General |
| 10/29/2021 | Otsuka Pharmaceutical Co., Ltd. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 10/19/2021 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $3,575.00 | General |
| 03/12/2021 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| 11/04/2020 | Merck Sharp & Dohme Corporation | — | Consulting Fee | Cash or cash equivalent | $4,050.00 | General |
| 06/16/2020 | Mallinckrodt Hospital Products Inc. | — | Consulting Fee | Cash or cash equivalent | $4,571.88 | General |
| 03/19/2020 | Intercept Pharmaceuticals, Inc. | — | Honoraria | Cash or cash equivalent | $3,600.00 | General |
| 03/19/2020 | Intercept Pharmaceuticals, Inc. | — | Travel and Lodging | Cash or cash equivalent | $60.59 | General |
| 03/19/2020 | Intercept Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $25.52 | General |
| 02/29/2020 | Intercept Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $282.50 | General |
| 02/29/2020 | Intercept Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $49.99 | General |
| 02/29/2020 | Intercept Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $42.13 | General |
| 02/29/2020 | Intercept Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $27.86 | General |
| 02/28/2020 | Intercept Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $120.00 | General |
| 02/25/2020 | Intercept Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $403.90 | General |
| 12/24/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $2,301.00 | Research |
| Study: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. • Category: GASTROENTEROLOGY | ||||||
| 11/10/2019 | Mallinckrodt Enterprises LLC | — | Food and Beverage | In-kind items and services | $72.85 | General |
| 06/12/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $2,301.00 | Research |
| Study: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. • Category: GASTROENTEROLOGY | ||||||
| 06/12/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $2,301.00 | Research |
| Study: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. • Category: GASTROENTEROLOGY | ||||||
| 06/12/2019 | Bausch Health US, LLC | XIFAXAN (Drug) | — | Cash or cash equivalent | $2,301.00 | Research |
| Study: A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. • Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF RIFAXIMIN SOLUBLE DISPERSION SSD TABLETS PLUS LACTULOSE AND RIFAXIMIN EXTENDED INTESTINAL RELEASE EIR TABLETS PLUS LACTULOSE FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY OHE. | Bausch Health US, LLC | $33,657 | 16 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-861 FOR THE TREATMENT OF NARCOLEPSY WITHOUT CATAPLEXY (NARCOLEPSY TYPE 2) | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | 1 |
| A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2) | Takeda Pharmaceuticals U.S.A., Inc. | $875.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 67 | 82 | $34,557 | $5,792 |
| 2022 | 6 | 188 | 253 | $93,061 | $15,769 |
| 2021 | 7 | 239 | 311 | $126,329 | $21,632 |
| 2020 | 5 | 145 | 202 | $62,926 | $13,307 |
Total Patients
639
Total Services
848
Medicare Billing
$56,500
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 26 | 26 | $11,050 | $2,557 | 23.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 32 | $7,360 | $1,915 | 26.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $14,080 | $832.57 | 5.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 12 | 13 | $2,067 | $487.37 | 23.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 55 | 88 | $20,240 | $4,404 | 21.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 42 | 44 | $18,700 | $4,287 | 22.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 53 | $18,550 | $3,641 | 19.6% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 37 | 43 | $6,837 | $1,260 | 18.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 13 | 14 | $17,108 | $1,248 | 7.3% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 11 | 11 | $11,626 | $929.33 | 8.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 56 | 59 | $24,970 | $5,994 | 24.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 64 | 101 | $23,080 | $5,645 | 24.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 30 | 48 | $16,305 | $3,856 | 23.7% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 11 | 12 | $15,696 | $1,735 | 11.1% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 22 | 22 | $22,242 | $1,719 | 7.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 43 | 56 | $8,904 | $1,652 | 18.6% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 13 | 13 | $15,132 | $1,030 | 6.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 54 | 86 | $19,103 | $4,832 | 25.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 38 | 38 | $15,788 | $4,052 | 25.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 26 | $7,903 | $2,111 | 26.7% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 26 | 38 | $6,007 | $1,159 | 19.3% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2020 | 14 | 14 | $14,125 | $1,153 | 8.2% |
About Dr. Don Rockey, MD
Dr. Don Rockey, MD is a Gastroenterology healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1679520175.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Don Rockey, MD has received a total of $593,484 in payments from pharmaceutical and medical device companies, with $11,949 received in 2024. These payments were reported across 207 transactions from 14 companies. The most common payment nature is "" ($536,391).
As a Medicare-enrolled provider, Rockey has provided services to 639 Medicare beneficiaries, totaling 848 services with total Medicare billing of $56,500. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology, Hepatology
- Location Charleston, SC
- Active Since 05/28/2006
- Last Updated 03/02/2022
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1679520175
Products in Payments
- sGC $501,267
- XIFAXAN (Drug) $33,657
- OCALIVA (Drug) $7,417
- RIFAXIMIN (Drug) $71.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Charleston
Mark Delegge, Md, MD
Gastroenterology — Payments: $666,913
Gastroenterology $666,913
Erin Forster, M.d, M.D
Gastroenterology — Payments: $597,594
Gastroenterology $597,594
Peter Cotton, Md, MD
Gastroenterology — Payments: $519,256
Gastroenterology $519,256
Dr. John Litchfield, Do, DO
Gastroenterology — Payments: $42,542
Gastroenterology $42,542
Brenda Hoffman, Md, MD
Gastroenterology — Payments: $17,605
Gastroenterology $17,605
Dr. David Koch, M.d, M.D
Gastroenterology — Payments: $12,773
Gastroenterology $12,773